Gilead Sciences says remdesivir reduces risk of death in COVID-19 patients

Researchers from biopharmaceutical company Gile Sciences said that COVID-19 patients ministered with antiviral drug remdesivir h better recovery and ir conditions improved, thus reducing  mortality rates. In a study published on July 10, Gile conducted Comparative Analysis of Clinical Recovery and Mortality Outcomes from Phase 3 SIMPLE Trial.  researchers compared 312 people hospitalized from COVID-19 disease. 

As per study, remdesivir was associated with an improvement in clinical recovery and a 62 percent reduction in risk of mortality compared with standard of care. Furr, an evaluation of safety and efficacy of remdesivir across different racial and ethnic patient subgroups was conducted in US which found similar clinical outcomes as overall patient population in study. Remdesivir medicine shortened hospital recovery times for extremely critical patients, according to data in April from a separate US government trial, published in Gile's late-st study.  

Doctor at Columbia University Irving Medical Center, Susan Olender said, study served as an important junct to clinical trial data even as it is t as vigorous as a randomized controlled trial. Merd Parsey, MD, PhD, Chief Medical Officer, Gile Sciences said that to dress urgency of continuing pandemic, “We are working to broen our understanding of full utility of remdesivir.” He ded, “we are sharing data with research community as quickly as possible with goal of providing transparent and timely updates on new developments with remdesivir.” 

Re: NYIFF To Screen 40 Films, Documentaries At Virtual Edition Amid Coronavirus Pandemic

Re: Coronavirus Lockdown Won’t Impact 3-month Cheque Validity, Rules SC

74.4 per cent recovered

As per statement published by Gile, at least 74.4 percent of remdesivir-treated COVID-19 severe patients h recovered by Day 14 versus 59.0 patients receiving standard of care. ditionally,  mortality rate for se patients was 7.6 percent on Day 14, while patients on standard care h mortality rate of 12.5 percent. However, a professor at University of Pittsburgh’s medical school, Walid Gell said it might t be necessary, relation of clinical trial data and observational data with mortality. He said, “ mortality in  remdesivir trials has generally been lower for both control and intervention groups than or trials and or real-world cohorts I've seen.”  

Re: Hong Kong To Shut Schools Amid Increase In Fresh Coronavirus Cases

Re: Iowa Sees One-day Surge Of 744 Confirmed Coronavirus Cases